0000899243-20-030415.txt : 20201104
0000899243-20-030415.hdr.sgml : 20201104
20201104200020
ACCESSION NUMBER: 0000899243-20-030415
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201102
FILED AS OF DATE: 20201104
DATE AS OF CHANGE: 20201104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pedersen Anders
CENTRAL INDEX KEY: 0001825779
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39655
FILM NUMBER: 201288235
MAIL ADDRESS:
STREET 1: C/O GALECTO, INC.
STREET 2: OLE MAALOES VEJ 3
CITY: COPENHAGEN N
STATE: G7
ZIP: DK-2200
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Galecto, Inc.
CENTRAL INDEX KEY: 0001800315
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 371957007
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: GALECTO BIOTECH AB
STREET 2: OLE MAALOES VEJ3
CITY: COPENHAGEN
STATE: G7
ZIP: DK-2200
BUSINESS PHONE: 45-70-70-52-10
MAIL ADDRESS:
STREET 1: GALECTO BIOTECH AB
STREET 2: OLE MAALOES VEJ3
CITY: COPENHAGEN
STATE: G7
ZIP: DK-2200
FORMER COMPANY:
FORMER CONFORMED NAME: Galecto Inc.
DATE OF NAME CHANGE: 20200116
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-11-02
0
0001800315
Galecto, Inc.
GLTO
0001825779
Pedersen Anders
C/O GALECTO, INC.
OLE MAALOES VEJ 3
COPENHAGEN N
G7
DK-2200
DENMARK
0
1
0
0
Chief Operating Officer
Common Stock
2020-11-02
4
C
0
3746
A
3746
D
Stock Option (right to buy)
1.95
2020-06-24
4
A
0
142983
0.00
A
2030-06-24
Common Stock
142983
142983
D
Stock Option (right to buy)
7.70
2020-10-07
4
A
0
77991
0.00
A
2030-10-06
Common Stock
77991
77991
D
Series C-1 Preferred Stock
2020-11-02
4
C
0
1441
0.00
D
Common Stock
3746
0
D
The Series C-1 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series C-1 Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series C-1 Preferred Stock had no expiration date.
On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock ("Stock Split"). This amount has been adjusted to give effect to the Stock Split.
25% of the shares subject to such option vested and became exercisable on October 22, 2019 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
25% of the shares subject to such option vest and become exercisable on September 27, 2021 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.
/s/ Jonathan Freve, attorney-in-fact
2020-11-04